• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • ANNUAL GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Akari TX

Akari TX / June 25, 2025

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India Patent

Access the “What This Means” segment here BOSTON and LONDON – June 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …

[Read more...] about Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India Patent

Akari TX / June 18, 2025

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune …

[Read more...] about Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Akari TX / June 6, 2025

Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2025

AGM VOTING RESULTS (FORM 8-K) NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2025 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL …

[Read more...] about Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2025

Akari TX / May 29, 2025

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical …

[Read more...] about Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari TX / May 28, 2025

Meet Mark Kubik, Head of Business Development – Oncology

…

[Read more...] about Meet Mark Kubik, Head of Business Development – Oncology

Next Page »

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.